MARKET WIREBenzinga • 4d ago
Barclays Maintains Overweight on Omada Health, Lowers Price Target to $24Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and lowers the price target from $27 to $24.
Why OMDA Stock surged +2.45% Today — RQD Quant Desk Flash
$19.65 +2.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $19.70
Omada Health Inc. (OMDA) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $1.20B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on OMDA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Omada Health Inc. (NASDAQ: OMDA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $19.65 (+2.45% 1D, market cap $1.20B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, OMDA ranks #264 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OMDA compare to INNV and USPH in the Health Care sector?
▼
Within the Health Care sector (Medical/Nursing Services), OMDA carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 65.7%, and ROIC of -15.7%. By comparison, INNV (InnovAge Holding Corp.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC -10.2%, cap $1.26B) and USPH (U.S. Physical Therapy Inc.) posts a C grade (64/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.29B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OMDA?
▼
Per OMDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611115), Omada Health Inc. generated $260.2M in revenue (+53.2% YoY), -$12.8M in net income, and $16.9M in free cash flow against $305.4M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $19.70 (+0.25%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 6.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OMDA)Realized 20D OHLCV Swing Band: ±11.2%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY OMDA SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (29% of score)
Altman Z-Score 8.93 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 6.5% FCF Margin ($16.9M FCF) & 65.7% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$21.55-18.2% Next Q
64
Q2 (-2Q)Grade C$17.63+7.5% Next Q
61
Q3 (-1Q)Grade C$18.95+3.7% Next Q
59
CurrentGrade D+$19.65-0.4% Hist 90D α
56
Trajectory: C+ (64) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the OMDA Bull Thesis Could Fail
Even with a 56/100 (D+) score, OMDA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Dilution Drag (+1.64% YoY Shares) — any gross margin slip below 63.2% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($20.75) or 200D SMA ($17.68) invalidates the momentum regime and cuts Target Base ($19.47) toward Bear Floor ($15.19).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OMDA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OMDA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OMDA Stock surged +2.45% Today — RQD Quant Desk Flash
Omada Health Inc. (OMDA) surged +2.45% to $19.65, trading at 59% of its 52-week range ($10.28 – $26.13). Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 59% of its 52-week range ($10.28 – $26.13) with RSI-14 at 43.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.2% around $19.65 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 65.7% gross margin and $16.9M annual free cash flow.
Live OMDA Headlines & Catalysts
MARKET WIREYahoo • 10d ago
PRISM MarketView Highlights Five Innovative Public Companies Supporting Strength and Mobility for National Physical Therapy MonthOrthoPediatrics, Omada Health, Enovis, Myomo and FIGS span the full arc of physical therapy, from childhood care and prevention to recovery and the professionals who deliver it NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) --
RISK WATCHYahoo • 12d ago
Omada Health to Present Peer-Reviewed Research on Improving Weight Loss and Body Composition During GLP-1 Treatment at World Obesity and Weight Management CongressThe oral presentation will share results from a 12-week comparative study showing that Omada GLP-1 Care Track members, on average, lost more weight and saw greater improvements in body composition than controlsSAN FRANCI
RISK WATCHBenzinga • 12d ago
Omada Health To Present Published Research Showing That Members Of Its GLP-1 Care Track Lost More Weight And Experienced Greater Improvements In Body Composition Than GLP-1 Users Receiving Usual CareGLP-1 medications can produce rapid weight loss,2 but lean mass can account for 30% or more of the weight lost.3,4 Lean mass is critical for overall health, as losing lean mass may contribute to reductions in resting
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OMDA)
- ✓Walkthrough of OMDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OMDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +34.77%📐 HORIZONTAL RANGE
2026-10-30O $19.35H $19.65L $18.47C $19.65VOL 958.6K
RES: $26.98SUP: $17.34SMA50: $20.75SMA200: $17.68
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OMDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +53.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on OMDA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OMDA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OMDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OMDA)
Health Care Rank #264 of 1016
⚔️ INNV vs OMDA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OMDA vs. INNV, USPH, PNTG, TDOC)
Industry: Medical/Nursing Services (29 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Omada Health Inc. (OMDA) ranks #264 by composite RQD confidence (56/100, grade D+) and #338 by equity capitalization ($1.20B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with OMDA at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OMDA
ACTIVE
Omada Health Inc. | D+ | 56/100 | — | 65.7% | -15.7% | +2.45% | $1.20B | Benchmark Subject |
| INNV InnovAge Holding Corp. | D+ | 57/100 | — | 18.0% | -10.2% | +1.54% | $1.26B | /innv-vs-omda → |
| USPH U.S. Physical Therapy Inc. | C | 64/100 | 32.6x | 19.2% | 11.5% | +1.47% | $1.29B | /usph-vs-omda → |
| PNTG The Pennant Group Inc. | D+ | 56/100 | 50.2x | — | 11.0% | +0.76% | $1.48B | /pntg-vs-omda → |
| TDOC Teladoc Health Inc. | D+ | 56/100 | — | — | -17.0% | +26.89% | $1.59B | /tdoc-vs-omda → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001611115In its most recent audited fiscal period (FY2025, filed 2025-12-31), Omada Health Inc. (OMDA) reported GAAP revenue of $260.2M (+53.2% vs. FY2024 revenue of $169.8M , and +111.9% cumulative change since FY2023) , GAAP net income of -$12.8M, operating cash flow of $18.3M, and free cash flow of $16.9M (+148.7% YoY). On the balance sheet, OMDA closed FY2025 with $305.4M in total assets against $0 in total debt (Altman Z-Score: 8.93, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $260.2M | -$12.8M | $18.3M | $16.9M | $305.4M | — |
| FY2024 (FY) | 2024-12-31 | $169.8M | -$47.1M | -$34.2M | -$34.8M | $150.9M | — |
| FY2023 (FY) | 2023-12-31 | $122.8M | -$67.5M | -$49.7M | -$49.7M | — | — |
3. OMDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Omada Health Inc. (NASDAQ: OMDA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $19.65 (+2.45% 1D, market cap $1.20B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, OMDA ranks #264 in composite RQD confidence.
How does OMDA compare to INNV and USPH in the Health Care sector?
Within the Health Care sector (Medical/Nursing Services), OMDA carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 65.7%, and ROIC of -15.7%. By comparison, INNV (InnovAge Holding Corp.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC -10.2%, cap $1.26B) and USPH (U.S. Physical Therapy Inc.) posts a C grade (64/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.29B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OMDA?
Per OMDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611115), Omada Health Inc. generated $260.2M in revenue (+53.2% YoY), -$12.8M in net income, and $16.9M in free cash flow against $305.4M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OMDA trading relative to its 50-day, 200-day, and 52-week technical levels?
OMDA last traded at $19.65 (+2.45% on volume of 620,107 shares), positioning the stock -5.30% below its 50-day simple moving average ($20.75) and +11.14% above its 200-day simple moving average ($17.68). Across its 52-week range of $10.28 to $26.13, OMDA sits at the 59.1% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($17.45 to $21.85).
OMDA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is OMDA stock moving today?
Why OMDA Stock surged +2.45% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.